Source: Blood advances. Unidade: FM
Subjects: ANEMIA, GLOBULINAS, FÁRMACOS
ABNT
FONSECA, Ana Rita da et al. Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates. Blood advances, v. 9, n. 4, p. 906-912, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/84790. Acesso em: 03 jan. 2026.APA
Fonseca, A. R. da, Justino, C. C., Molla, V. C. de, Yamakawa, P. E., Rabelo, I. B., Arnold, L., et al. (2025). Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates. Blood advances, 9( 4), 906-912. doi:10.1182/bloodadvances.2024014159NLM
Fonseca AR da, Justino CC, Molla VC de, Yamakawa PE, Rabelo IB, Arnold L, Kelly R, Grif M, Munir T, Velloso EDRP. Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates [Internet]. Blood advances. 2025 ; 9( 4): 906-912.[citado 2026 jan. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84790Vancouver
Fonseca AR da, Justino CC, Molla VC de, Yamakawa PE, Rabelo IB, Arnold L, Kelly R, Grif M, Munir T, Velloso EDRP. Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates [Internet]. Blood advances. 2025 ; 9( 4): 906-912.[citado 2026 jan. 03 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84790
